viewFutura Medical PLC

Futura Medical gets set to begin formal approval steps for erectile dysfunction drug

Futura Medical PLC’s (LON:FUR) James Barder talks to Proactive London’s Katie Pilbeam about the highlights in their half-year report which includes the latest on MED3000 - a topical treatment for Erectile Dysfunction.

Proceedings have begun for formal approval of the drug to be approved as a 'over the counter' medical device and clinically proven treatment for ED in Europe by an EU Notified Body¹.

Barder then goes on to talk about Futura's other products which include TPR100 – to treat inflammatory pain as well as CBD100 - Futura's formulation using Cannabidiol. The balance sheet shows a £1.06 million net loss in the period (30 June 2019: net loss £4.46 million). While cash resources currently sit at £2.62 million.


¹Notified Bodies are organisations designated by EU countries to oversee the approval of medical devices within the EU and the UK.

Quick facts: Futura Medical PLC

Price: 14.25 GBX

Market: AIM
Market Cap: £35 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...


Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18

2 min read